Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 4,086 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Steroid treatment Clear all
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00005596
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
1,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
108
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 17, 2026, 10:37 PM EDT
Terminated Phase 1 Interventional

Platelet Rich Plasma vs. Corticosteroid Injection in the Treatment of Partial Rotator Cuff Tears

NCT01688362
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
Platelet Rich Plasma (PRP), Corticosteroid
Biological · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804

NCT03118570
View directory record Official record
Conditions
Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III, Osteogenesis Imperfecta Type IV
Interventions
setrusumab, Calcium, Vitamin D, zoledronic acid (optional)
Drug · Dietary Supplement
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
12
States / cities
Birmingham, Alabama • Jacksonville, Florida • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 17, 2026, 10:37 PM EDT
Terminated Phase 1 Interventional

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

NCT03530683
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma
Interventions
Maplirpacept (PF-07901801), Azacitidine, Venetoclax, Carfilzomib, Dexamethasone, Anti-CD20 Targeting agent, Isatuximab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
62
States / cities
Los Angeles, California • Pasadena, California • Denver, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Advanced Cancer

NCT00004105
View directory record Official record
Conditions
Leukemia, Lymphoma, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
estramustine phosphate sodium, paclitaxel, vinorelbine ditartrate
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 2 Interventional

Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis

NCT00262405
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
zileuton, azathioprine/prednisone
Drug
Lead sponsor
University of Michigan
Other
Eligibility
35 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00459290
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
mifepristone
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
22
States / cities
Los Angeles, California • Hartford, Connecticut • New Britain, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 1 Interventional

Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC

NCT02913196
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Apalutamide, Abiraterone acetate, Docetaxel, Prednisone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Treatment Interruption of Natalizumab

NCT01071083
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
natalizumab, interferon beta 1-a, methylprednisolone, IV placebo, glatiramer acetate
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Cullman, Alabama • San Francisco, California • Fort Collins, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Progesterone Effect on Individuals Diagnoses With AD and PTSD.

NCT02187224
View directory record Official record
Conditions
Alcohol Dependence, Post-Traumatic Stress Disorder (PTSD)
Interventions
Progesterone, Placebo (for Progesterone)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia

NCT00003783
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, idarubicin, leucovorin calcium, mercaptopurine, methotrexate, prednisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
51
States / cities
Tucson, Arizona • Palo Alto, California • Sacramento, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Oct 17, 2026, 10:37 PM EDT
Terminated Phase 2 Interventional Results available

Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma

NCT00843310
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide (Revlimid), Melphalan, Dexamethasone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 2 Interventional

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder

NCT00274820
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
ascorbic acid, arsenic trioxide, dexamethasone, thalidomide
Dietary Supplement · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Results available

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT01308580
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabazitaxel (XRP6258), Prednisone (or Prednisolone)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
21
States / cities
Muscle Shoals, Alabama • Hot Springs, Arkansas • Anaheim, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Results available

12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device

NCT01623310
View directory record Official record
Conditions
Nasal Polyps
Interventions
Fluticasone Propionate
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
16
States / cities
Birmingham, Alabama • Brandon, Florida • Normal, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 17, 2026, 10:37 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

NCT03732820
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
olaparib, abiraterone acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years · Male only
Enrollment
895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
28
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

NCT00107380
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, tositumomab and iodine I 131 tositumomab
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
78
States / cities
Anchorage, Alaska • Tucson, Arizona • Duarte, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Oct 17, 2026, 10:37 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Fractionated 1927-nm Non Ablative Thulium Laser in Treating Post Inflammatory Hyperpigmentation

NCT06149780
View directory record Official record
Conditions
Healthy
Interventions
Patients treated with laser
Device
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 4 Interventional

Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome

NCT00560586
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Budesonide, placebo
Drug
Lead sponsor
University of Louisville
Other
Eligibility
6 Years to 12 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Results available

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

NCT05468320
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Corticosteroids, anti-CD20 antibody
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Baltimore, Maryland • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 1 Interventional

High-Dose Chemotherapy Followed by Total-Body Irradiation and Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia

NCT00002788
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, cyclophosphamide, dexamethasone, etoposide, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
17 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 15, 2010 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 2 Interventional

Solitary Islet Transplantation for Type 1 Diabetes Mellitus Using Steroid Sparing Immunosuppression

NCT00006505
View directory record Official record
Conditions
Diabetes Mellitus Type 1
Interventions
Islet Transplantation
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 2 Interventional

Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80

NCT00163566
View directory record Official record
Conditions
Hypogonadism, Late Onset Hypogonadism, Low Testosterone
Interventions
Dihydrotestosterone (0.7%) in hydroalcoholic gel
Drug
Lead sponsor
ASCEND Therapeutics
Industry
Eligibility
55 Years to 80 Years · Male only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
16
States / cities
Phoenix, Arizona • Torrance, California • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 17, 2026, 10:37 PM EDT
Not listed Early Phase 1 Interventional

Spinal Fusions Steroid Study

NCT05287035
View directory record Official record
Conditions
Spinal Fusion
Interventions
Dexamethasone injection, Saline injection
Drug · Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
10 Years to 18 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 17, 2026, 10:37 PM EDT